<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00601692</url>
  </required_header>
  <id_info>
    <org_study_id>02-061</org_study_id>
    <secondary_id>P30CA008748</secondary_id>
    <secondary_id>MSKCC-02061</secondary_id>
    <secondary_id>SANOFI-AVENTIS-MSKCC-02061</secondary_id>
    <nct_id>NCT00601692</nct_id>
  </id_info>
  <brief_title>Irinotecan, Radiation Therapy, and Docetaxel With or Without Cisplatin in Treating Patients With Locally Advanced Esophageal Cancer</brief_title>
  <official_title>A Phase I Trial of Irinotecan, Radiation Therapy and Escalating Doses of Docetaxel With Cisplatin in Locally Advanced Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Irinotecan may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells.&#xD;
      Irinotecan and docetaxel may also make tumor cells more sensitive to radiation therapy.&#xD;
      Giving combination chemotherapy together with radiation therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of docetaxel when&#xD;
      given together with irinotecan and radiation therapy with or without cisplatin in treating&#xD;
      patients with locally advanced esophageal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the dose limiting toxicity and recommended phase II dose of docetaxel when&#xD;
           given at escalating doses with weekly irinotecan hydrochloride and concurrent&#xD;
           radiotherapy in patients with locally advanced esophageal cancer.&#xD;
&#xD;
        -  To determine the dose limiting toxicity of cisplatin, once the recommended phase II dose&#xD;
           of docetaxel is established, when given weekly with docetaxel, irinotecan hydrochloride,&#xD;
           and concurrent radiotherapy in patients with locally advanced esophageal cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To evaluate the clinical and pathological complete response rate in patients with&#xD;
           locally advanced esophageal cancer treated with induction chemotherapy comprising&#xD;
           docetaxel and irinotecan hydrochloride with or without cisplatin followed by concurrent&#xD;
           docetaxel and irinotecan hydrochloride with or without cisplatin plus radiotherapy.&#xD;
&#xD;
      OUTLINE: Patients receive one of the following regimens. Regimen 2 is for patients recruited&#xD;
      after the recommended phase II dose has been determined in patients recruited (who receive&#xD;
      regimen 1).&#xD;
&#xD;
        -  Regimen 1:&#xD;
&#xD;
             -  Induction chemotherapy (weeks 1-6): Patients receive docetaxel IV over 15 minutes&#xD;
                and irinotecan hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats&#xD;
                every 3 weeks for 2 courses in the absence of disease progression or unacceptable&#xD;
                toxicity.&#xD;
&#xD;
             -  Chemoradiotherapy (weeks 8-13): Beginning in week 8, patients receive docetaxel IV&#xD;
                over 15 minutes and irinotecan hydrochloride IV over 30 minutes on days 1 (week 8)&#xD;
                and 8 (week 9). Patients also undergo radiotherapy once daily, 5 days a week, in&#xD;
                weeks 8-10. Treatment with chemoradiotherapy repeats every 3 weeks for 2 courses in&#xD;
                the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Regimen 2:&#xD;
&#xD;
             -  Induction chemotherapy (weeks 1-6): Patients receive docetaxel IV and irinotecan&#xD;
                hydrochloride as in regimen 1 induction chemotherapy. They also receive cisplatin&#xD;
                IV over 20-30 minutes on days 1 and 8. Treatment with irinotecan hydrochloride,&#xD;
                docetaxel, and cisplatin repeats every 3 weeks for 2 courses in the absence of&#xD;
                disease progression or unacceptable toxicity.&#xD;
&#xD;
             -  Chemoradiotherapy (weeks 8-13): Patients receive docetaxel IV, irinotecan&#xD;
                hydrochloride IV, and undergo radiotherapy as in regimen 1 chemoradiotherapy.&#xD;
                Patients also receive cisplatin IV over 20-30 minutes on days 1 (week 8) and 8&#xD;
                (week 9). Treatment with irinotecan hydrochloride, docetaxel, cisplatin, and&#xD;
                radiotherapy repeats every 3 weeks for 2 courses in the absence of disease&#xD;
                progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 2 years, every&#xD;
      6 months for 3 years, and then annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of docetaxel when administered together with irinotecan hydrochloride and radiotherapy</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical and pathological complete response rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive docetaxel IV over 15 minutes and irinotecan hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning in week 8, patients receive docetaxel IV over 15 minutes and irinotecan hydrochloride IV over 30 minutes on days 1 (week 8) and 8 (week 9). Patients also undergo radiotherapy once daily, 5 days a week, in weeks 8-10. Treatment with chemoradiotherapy repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive docetaxel IV and irinotecan hydrochloride as in regimen 1 induction chemotherapy. They also receive cisplatin IV over 20-30 minutes on days 1 and 8. Treatment with irinotecan hydrochloride, docetaxel, and cisplatin repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients receive docetaxel IV, irinotecan hydrochloride IV, and undergo radiotherapy as in regimen 1 chemoradiotherapy. Patients also receive cisplatin IV over 20-30 minutes on days 1 (week 8) and 8 (week 9). Treatment with irinotecan hydrochloride, docetaxel, cisplatin, and radiotherapy repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_label>Regimen 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_label>Regimen 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Given 5 days a week for 3 weeks</description>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_label>Regimen 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Histologically confirmed squamous cell carcinoma, adenocarcinoma, poorly&#xD;
             differentiated carcinoma, or carcinoma not otherwise specified, of the esophagus or&#xD;
             gastroesophageal (GE) junction&#xD;
&#xD;
               -  Disease clinically limited to the esophagus or GE junction (T1, N1, M0, or T2-4,&#xD;
                  any N, M0)&#xD;
&#xD;
               -  M1a metastatic disease to lymph nodes allowed&#xD;
&#xD;
                    -  Includes celiac lymph nodes in a patient with a distal third esophageal&#xD;
                       primary lesion or a gastroesophageal junction primary or supraclavicular&#xD;
                       lymph nodes in a patient with a proximal third esophageal lesion&#xD;
&#xD;
               -  Disease must be able to be contained in a radiotherapy field&#xD;
&#xD;
          -  Previously untreated patients with primary tumors of the cervical or thoracic&#xD;
             esophagus, including the GE junction, are eligible for this study&#xD;
&#xD;
               -  At least 50% of the tumor must involve the distal esophagus for tumors of the GE&#xD;
                  junction&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Positive malignant cytology of the pleura, pericardium, or peritoneum&#xD;
&#xD;
          -  Metastatic disease to distant organs (e.g. liver) or non-regional lymph nodes&#xD;
&#xD;
          -  Biopsy proven tumor invasion of the tracheobronchial tree or tracheo-esophageal&#xD;
             fistula&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Karnofsky performance status (PS) 70-100% OR ECOG PS 0-2&#xD;
&#xD;
          -  ANC ≥ 1,500 cells/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 mg/dL&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Total serum bilirubin ≤ 1.0 mg/dL&#xD;
&#xD;
          -  AST ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
          -  Men and women of child bearing potential must use effective contraception while on&#xD;
             treatment and for a reasonable period thereafter&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  History of severe hypersensitivity reaction to docetaxel or other drugs formulated&#xD;
             with polysorbate 80&#xD;
&#xD;
          -  Pre-existing peripheral neuropathy &gt; grade 1&#xD;
&#xD;
          -  Severe comorbid conditions including, but not limited to, any of the following:&#xD;
&#xD;
               -  NYHA class III-IV cardiac disease&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months&#xD;
&#xD;
               -  Severe uncontrolled diabetes&#xD;
&#xD;
               -  Hypercalcemia&#xD;
&#xD;
               -  Uncontrolled hypertension&#xD;
&#xD;
               -  Cerebral vascular disease&#xD;
&#xD;
               -  Uncontrolled infections&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  History of prior malignancy diagnosed and/or treated within the past three years,&#xD;
             except for basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the&#xD;
             cervix, or superficial transitional cell carcinoma of the bladder&#xD;
&#xD;
          -  Known Gilbert disease&#xD;
&#xD;
          -  History of seizure disorder with concurrent phenytoin, phenobarbital, or other&#xD;
             antiepileptic medication&#xD;
&#xD;
          -  Any other concurrent medical or psychiatric condition or disease that, in the&#xD;
             investigator's judgment, would make the patient inappropriate for entry into this&#xD;
             study&#xD;
&#xD;
          -  Patients who cannot fully comprehend the therapeutic implications of the protocol or&#xD;
             comply with the requirements&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy or radiotherapy (RT) for this esophageal cancer&#xD;
&#xD;
          -  No prior mantle RT, chest RT, pelvic RT, or hemi-body RT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David H. Ilson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>January 17, 2008</study_first_submitted>
  <study_first_submitted_qc>January 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2008</study_first_posted>
  <last_update_submitted>March 21, 2013</last_update_submitted>
  <last_update_submitted_qc>March 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>squamous cell carcinoma of the esophagus</keyword>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <keyword>stage II esophageal cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

